Over 8,000 experts from all over the world participated in the ISTH – International Society on Thrombosis and Haemostasis Biannual Congress, the most important global event dedicated to thrombosis, hemostasis and vascular biology, which this year was held in Berlin, Germany on July 8-13. Inhibitors and customized prophylaxis were the topics discussed the most by hemostasis KOLs attending the event.
Kedrion Biopharma attended with a booth and a large delegation of international guests. The company also organized the symposium SIPPET Study: One Year Later. New Insights to Help Manage “My Next Patient”, chaired by Prof. Flora Peyvandi on 9 July. Starting with an overview of the SIPPET study, and moving on to examine the reactions to it published by the different communities of stakeholders and the sub-analyses ensuing from it, the event closed with a round table aimed at encouraging the audience to reflect on how the study’s results could be integrated into the decision-making process concerning the therapeutic choices available for Previously Untreated Patients.
Moreover, Kedrion contributed to Octapharma’s symposium Towards Life Without Limitations: Growing Experience with Nuwiq® in Patients with Hemophilia A, which was held on the same day. Chaired by Prof. Pier Mannuccio Mannucci, it featured a lecture by Dr. Massimo Morfini reporting data on the use of the product to carry out personalized prophylaxis in Italy.
